New combo therapy shows promise for kids with aggressive leukemia
NCT ID NCT03591510
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug midostaurin to standard chemotherapy helps children with a certain genetic type of acute myeloid leukemia (FLT3-mutated AML). About 22 children will receive the drug twice daily alongside chemo, then continue midostaurin alone for 12 more cycles. The goal is to see if the combination is safe and helps control the disease, but ongoing treatment may be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FLT3-MUTATED ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Prague, 150 06, Czechia
-
Novartis Investigative Site
Berlin, 13353, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Pavia, PV, 27100, Italy
-
Novartis Investigative Site
Roma, RM, 00165, Italy
-
Novartis Investigative Site
Torino, TO, 10126, Italy
-
Novartis Investigative Site
Naples, 80122, Italy
-
Novartis Investigative Site
Osaka, 5340021, Japan
-
Novartis Investigative Site
Amman, 11941, Jordan
-
Novartis Investigative Site
Krakow, 30-663, Poland
-
Novartis Investigative Site
Moscow, 117198, Russia
-
Novartis Investigative Site
Ljubljana, 1000, Slovenia
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 05505, South Korea
-
Novartis Investigative Site
Adana, Adana, 1330, Turkey (Türkiye)